Annals of Clinical Nutrition and Metabolism : eISSN 2799-8363 / pISSN 2799-7898

Table. 1.

Table. 1.

Laboratory test results and remarkable clinical characteristics according to net energy intake before resumption of oral intake

Admission Op day POD 1 POD 2 POD 3 POD 4
Infused caloric fluid 5% DNK1 1,440 mL 5% DNK1 1,440 mL Winuf®peria 1,450 mL 5% DNK1 1,440 mL 5% DNK1 1,440 mL 5% DNK1 1,440 mL
Total calorie (kcal) 244.8 244.8 1,004 244.8 244.8 244.8

Biochemical parameters (reference range)
White blood cell count (/μL) (4,000~10,000) 3,960 9,110 14,830 16,470 14,250 8,960
Hemoglobin (g/dL) (13.1~17.5) 10.6 10.0 10.9 9.9 9.2 8.4
Hematocrit (%) (39.0~52.0) 35.2 31.8 35.9 31.3 28.9 26.2
Platelet count (×1,000/μL) (140~400) 166 146 127 90 62 56
Na (mEq/l) (133~145) NP 138 135 136 134 133
K (mEq/l) (3.5~5.5) NP 4.26 4.80 4.9 4.3 3.7
Cl (mEq/l) (95~110) NP 105 103 107 104 102
Calcium (mg/dL) (8.6~10.7) 8.5 7.8 8.7 10.1 9.1 8.4
Phosphate (mg/dL) (2.5~4.5) 1.5 2.0 2.1 1.9 1.9 1.5
Glucose (mg/dL) (70~100) 89 114 157 98 124 114
Albumin (mg/dL) (3.5~5.2) 3.6 2.7 2.8 3.2 2.6 2.6
BUN (mg/dL) (6~20) 11.5 9.4 11.7 25.9 27.0 20.8
Creatinine (mg/dL) (0.5~1.2) 0.97 1.02 1.09 1.07 1.29 1.08

Intake/output (mL/mL) NP 1,950/820 5,100/1,060 4,400/2,615 3,150/2,900 3,000/2,685
Intraperitoneal drainage amount (mL) 310 320 530 900 585

Injections Hartmann’s solution Calcium gluconate 10% 40 mL 20% albumin 100 mL Volulyte®b 6% 500 mL Hartmann’s solution Tamipool®c 1 ampoule Levofloxacin 750 mg Piperacillin/ tazobactam 4.5 g Hartmann’s solution 20% albumin 100 mL Levofloxacin 750 mg Piperacillin/tazobactam 4.5 g Hartmann’s solution KH2PO4 20 mL 20% albumin 100 mL Levofloxacin 750 mg Piperacillin/tazobactam 4.5 g

Body weight (kg) 50.9 51.2 53.8 56.1 58.8 59.0
Notable clinical features HAP with bilateral pleural effusion Pitting edema HAP with bilateral pleural effusion Pitting edema HAP with bilateral pleural effusion

Op = operation; POD = postoperative day; 5% DNK1 = dextrose 5% (187 kcal/bag); NP = not performed; HAP = hospital-acquired pneumonia.

aWinuf®peri (JW Pharmaceutical, Seoul, Korea); bVolulyte® (Fresenius Kabi Deutschland GmbH, Friedberg, Germany); cTamipool® (BCWP, Yeoju, Korea).

Ann Clin Nutr Metab 2022;14:88-92 https://doi.org/10.15747/ACNM.2022.14.2.88
© 2022 Ann Clin Nutr Metab